| Autor: |
Shumei Kato, Bing Li, Adashek, Jacob J., Seong Won Cha, Bianchi-Frias, Daniella, Dajun Qian, Kim, Lisa, Wso, Tiffany, Mitchell, Marcus, Naoki Kamei, Hoiness, Robert, Hoo, Jayne, Gray, Phillip N., Iyama, Teruaki, Kashiwagi, Masahide, Hsiao-Mei Lu, Kurzrock, Razelle |
| Předmět: |
|
| Zdroj: |
OncoImmunology; 2022, Vol. 11 Issue 1, p1-9, 9p |
| Abstrakt: |
Major immunotherapy challenges include a limited number of predictive biomarkers and the unusual imaging features post-therapy, such as pseudo-progression, which denote immune infiltratemediated tumor enlargement. Such phenomena confound clinical decision-making, since the cancer may eventually regress, and the patient should stay on treatment. We prospectively evaluated serial, blood-derived cell-free DNA (cfDNA) (baseline and 2-3 weeks post-immune checkpoint inhibitors [ICIs]) for variant allele frequency (VAF) and blood tumor mutation burden (bTMB) changes (nextgeneration sequencing) (N = 84 evaluable patients, diverse cancers). Low vs. high cfDNA-derived average adjusted ΔVAF (calculated by a machine-learning model) was an independent predictor of higher clinical benefit rate (stable disease =6 months/complete/partial response) (69.2% vs. 22.5%), and longer median progression-free (10.1 vs. 2.25 months) and overall survival (not reached vs. 6.1 months) (all P < .001, multivariate). bTMB changes did not correlate with outcomes. Therefore, early dynamic changes in cfDNA-derived VAF were a powerful predictor of pan-cancer immunotherapy outcomes. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
